ER + Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors.

MLA

Guerrero-Zotano, Angel L., et al. “ER + Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 24, no. 11, June 2018, pp. 2517–29. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-17-2904.

APA

Guerrero-Zotano, A. L., Stricker, T. P., Formisano, L., Hutchinson, K. E., Stover, D. G., Lee, K.-M., Schwarz, L. J., Giltnane, J. M., Estrada, M. V., Jansen, V. M., Servetto, A., Gavilá, J., Perez-Fidalgo, J. A., Lluch, A., Llombart-Cussac, A., Bayar, M. A., Michiels, S., André, F., Arnedos, M., … Arteaga, C. L. (2018). ER + Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 24(11), 2517–2529. https://doi.org/10.1158/1078-0432.CCR-17-2904

Chicago

Guerrero-Zotano, Angel L, Thomas P Stricker, Luigi Formisano, Katherine E Hutchinson, Daniel G Stover, Kyung-Min Lee, Luis J Schwarz, et al. 2018. “ER + Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 24 (11): 2517–29. doi:10.1158/1078-0432.CCR-17-2904.